Supernus Pharmaceuticals, Inc. (SUPN) — Business segments and KPIs
Revenue by business segment and geography for Supernus Pharmaceuticals, Inc., with year-over-year trends.
FY 2025
| Segment | Revenue | % of total |
|---|---|---|
| Revenue by product | ||
| Product | 626.54M | 47.2% |
| Qelbree | 304.65M | 22.9% |
| GOCOVRI | 146.82M | 11.1% |
| Collaboration Revenue | 53.00M | 4.0% |
| APOKYN | 47.77M | 3.6% |
| Trokendi Xr | 42.42M | 3.2% |
| Oxtellar X R | 40.70M | 3.1% |
| Royalty, License And Other Revenue | 39.42M | 3.0% |
| Manufactured Product, Other | 26.91M | 2.0% |